MX2021012871A - Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas. - Google Patents

Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.

Info

Publication number
MX2021012871A
MX2021012871A MX2021012871A MX2021012871A MX2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A
Authority
MX
Mexico
Prior art keywords
antibody
generation
polypeptide chain
derived polypeptides
chain exchange
Prior art date
Application number
MX2021012871A
Other languages
English (en)
Inventor
Guy Georges
Ulrich Brinkmann
Eike Hoffmann
Stefan Dengl
Sabine Imhof-Jung
Steffen Dickopf
Can Martin Buldun
David Zilian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021012871A publication Critical patent/MX2021012871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un conjunto de polipéptidos heterodiméricos y sus usos, por ejemplo, para generar aglutinantes de antígenos multiespecíficos mediante el intercambio de cadenas polipeptídicas.
MX2021012871A 2019-04-25 2020-04-24 Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas. MX2021012871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171068 2019-04-25
PCT/EP2020/061412 WO2020216878A1 (en) 2019-04-25 2020-04-24 Generation of antibody-derived polypeptides by polypeptide chain exchange

Publications (1)

Publication Number Publication Date
MX2021012871A true MX2021012871A (es) 2021-11-17

Family

ID=66334197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012871A MX2021012871A (es) 2019-04-25 2020-04-24 Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.

Country Status (12)

Country Link
US (1) US20220033525A1 (es)
EP (1) EP3959244A1 (es)
JP (1) JP2022531128A (es)
KR (1) KR20220005031A (es)
CN (1) CN113728002B (es)
AU (1) AU2020261250A1 (es)
BR (1) BR112021020843A2 (es)
CA (1) CA3132275A1 (es)
IL (1) IL287400A (es)
MX (1) MX2021012871A (es)
TW (1) TW202106714A (es)
WO (1) WO2020216878A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PL3227332T3 (pl) * 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
AU2021397322A1 (en) * 2020-12-10 2023-07-06 Invenra Inc. Orthogonal mutations for heterodimerization
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
EP2519541A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Ron binding constructs and methods of use thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
ES2971444T3 (es) * 2011-10-11 2024-06-05 F Hoffmann Lar Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
NZ799532A (en) * 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
JP6385357B2 (ja) * 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
PL3227332T3 (pl) * 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
RU2745648C2 (ru) * 2016-07-19 2021-03-30 Ибентрус, Инк. Биспецифические белки и способы их получения
KR20200067197A (ko) * 2017-10-20 2020-06-11 에프. 호프만-라 로슈 아게 단일특이적 항체로부터 다중특이적 항체의 생성 방법
BR112020007736A2 (pt) * 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
US20210324108A1 (en) * 2017-11-01 2021-10-21 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies

Also Published As

Publication number Publication date
IL287400A (en) 2021-12-01
CN113728002A (zh) 2021-11-30
KR20220005031A (ko) 2022-01-12
EP3959244A1 (en) 2022-03-02
TW202106714A (zh) 2021-02-16
WO2020216878A1 (en) 2020-10-29
CN113728002B (zh) 2024-11-12
JP2022531128A (ja) 2022-07-06
CA3132275A1 (en) 2020-10-29
BR112021020843A2 (pt) 2022-02-01
AU2020261250A1 (en) 2021-10-14
US20220033525A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2021012871A (es) Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
MX2020011353A (es) Fabricacion de clinker por oxicombustibles sin recirculacion de los gases de escape de precalentador.
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
PE20191150A1 (es) Receptores de celulas t con apareamiento mejorado
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CL2011000632A1 (es) Anticuerpo humanizado anti-receptor de interleuquina 6 (il-6); regiones variables y cadenas pesadas o livianas de los mismos; secuencia nucleotídica que lo codifica; vector; célula huésped; método de producción; y composición farmacéutica que lo comprende.
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
AR113092A1 (es) Métodos para fabricar receptores de antígeno quiméricos biespecíficos anti-cd307e y anti-bcma y usos de los mismos
CO2019006018A2 (es) Polimorfos de sepiapterina y sus sales
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
ECSP19055179A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2018002639A1 (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn.
CO2019012957A2 (es) Inhibidores de quinasa y usos de los mismos
MX2017013150A (es) Intermediarios quimicos derivados de biomasa.
MX2018008218A (es) Combustor en forma de u y metodo para uso en plantas cementeras.
ECSP20075234A (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
DOP2020000074A (es) Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
MX2019003030A (es) Catalizador que contiene ni para la oligomerizacion de olefinas.
BR112023003337A2 (pt) Receptores de antígeno quimérico bcma
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
CO2022000748A2 (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.